drugset / Trial / NCT01934335

Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

NCT01934335

Phase 2 Terminated 12 enrolled Ronald Weigel AstraZeneca · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this project is to examine whether treatment with vandetanib has an effect on the tumor cells in breast cancer by examining tissue markers.

Timeline

Start
2013-10
Primary completion
2018-12-21
Completion
2018-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Vandetanib Small molecule 300 mg Oral